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Abstract
Melanocytic nevi are a benign clonal proliferation of cells expressing the melanocytic phenotype, 
with heterogeneous clinical and molecular characteristics. In this review, we discuss the genetics 
of nevi by salient nevi subtypes: congenital melanocytic nevi, acquired melanocytic nevi, blue 
nevi, and Spitz nevi. While the molecular etiology of nevi has been less thoroughly studied than 
melanoma, it is clear that nevi and melanoma share common driver mutations. Acquired 
melanocytic nevi harbor oncogenic mutations in BRAF, which is the predominant oncogene 
associated with melanoma. Congenital melanocytic nevi and blue nevi frequently harbor NRAS 
mutations and GNAQ mutations, respectively, while Spitz and atypical Spitz tumors often exhibit 
HRAS and kinase rearrangements. These initial “driver” mutations are thought to trigger the 
establishment of benign nevi. After this initial phase of cell proliferation, a senescence program is 
executed, causing termination of nevi growth. Only upon the emergence of additional tumorigenic 
alterations, which may provide an escape from oncogene-induced senescence, can malignant 
progression occur. Here, we review the current literature on the pathobiology and genetics of nevi 
in the hope that additional studies of nevi promise to inform our understanding of the transition 
from benign neoplasm to malignancy.
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Introduction
The term “melanocytic neoplasm” is used to describe the presence of melanocytic cells in 
epidermal nests, which are defined as three or more melanocytic cells in direct contact, 
within the dermis or other tissues. Melanocytic neoplasms represent a diverse group of 
tumors that can be either benign (nevi) or malignant (melanoma). Nevi are believed to be 
benign clonal proliferations of cells expressing the melanocytic phenotype (Magana-Garcia 
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and Ackerman, 1990). The development of melanocytic nevi is a multifactorial and 
heterogeneous biologic process, and the molecular events resulting in melanocytic 
neoplasms are multifold and only beginning to be unraveled. In contrast to the extensive and 
genome-wide studies of melanomas, studies of benign melanocytic lesions have been 
restricted to mutational analyses targeting genes classically involved in melanomagenesis 
(Papp et al., 2003; Pollock et al., 2003). This lack of comprehensive molecular profiling is 
partly an artifact of limited nevi tissue availability after clinically biopsied samples are 
processed for histologic diagnoses. In melanoma, BRAF and NRAS gene mutations have 
been used as genetic markers in studies attempting to integrate genetic and morphologic 
features to improve classification (Cancer Genome Atlas Network. Electronic address and 
Cancer Genome Atlas, 2015; Pozzobon et al., 2014; Viros et al., 2008). BRAF is a serine-
threonine kinase that is activated by the RAS family of proteins. Once activated, it triggers 
the MAPK signaling cascade that ultimately leads to cell cycle progression, upregulation of 
transcription, and differentiation. NRAS is one of the three major isoforms of the RAS family 
of GTPase proteins that are involved in cell growth, differentiation, and survival. A high 
frequency of oncogenic BRAF mutations at a V660E in the kinase domain of exon 15 has 
been reported in melanomas and melanocytic nevi, suggesting mutational activation of the 
RAS/RAF/MEK/ERK pathway is a critical step in the development of these melanocytic 
tumors (Davies et al., 2002; Pollock et al., 2003) (Figure 1).
In contrast to the various mouse models developed to investigate the molecular events 
underlying melanomagenesis, there are few models to investigate nevus development. The 
first model system employed targeted overexpression of BRAFV600E in the melanocyte 
compartment of transgenic zebrafish, which caused proliferation of melanocytes, producing 
fish nevi (Patton et al., 2005). Similarly, in mice, expression of BRAFV600E in the 
melanocytic lineage produced nevi with signs of senescence (Goel et al., 2009). Most 
recently, a mouse model has been developed that closely resembles nevi in humans. In this 
model, BRAFV600E was conditionally expressed from its endogenous promoter and 
restricted to melanocytes (Dankort et al., 2009) (Dhomen et al., 2009). Also, pigmented 
hairless mice with genetic deficiencies in Ink4a/Arf and Xpa genes can produce nevi (~1 to 2 
per mouse), but none advance to melanoma (van Schanke et al., 2006). Also, a substantial 
proportion of these mice remain nevus-free, thus limiting their use as a model for nevus 
development. Nasti et al. developed a mouse model of nevus initiation and progression with 
C3H/HeN mice using a modified chemical carcinogenesis protocol (Nasti et al., 2015). In 
this model, dysplastic pigmented skin lesions appeared in 7–9 weeks with 100% penetrance 
and nests of melanocytic cells appeared in a subset of skin draining lymph nodes. This 
model may yield insight into acquired mutations at the early stages of nevus initiation and 
promotion of nevus cell transformation. However, additional nevus/melanoma models are 
needed to identify genetic underpinnings of nevus formation, novel oncogenic pathways, 
targets for immune-prevention, and mechanisms of nevus development.
Benign melanocytic neoplasms can be sub-categorized based on clinical and histological 
characteristics. Common subgroups include congenital melanocytic nevi (CMN), acquired 
melanocytic nevi, blue nevi, and Spitz nevi (Figure 2). We will discuss the genetics of nevi 
by type.
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CONGENITAL MELANOCYTIC NEVI
Congenital melanocytic nevi (CMN) overwhelmingly occur in a sporadic pattern, with rare 
reports of familial cases, and as such are believed to result from somatic mutations in utero 
(Charbel et al., 2014). There have been several studies seeking to identify genetic hits 
underlying CMN pathogenesis, and the aggregate results of these studies suggest NRAS 
mutations and, to a lesser extent, BRAF mutations, contribute to the development of CMN 
(Table 1). The literature on the molecular characterization of CMN often cites discrepancies 
between studies demonstrating a high prevalence of BRAF mutations (Ichii-Nakato et al., 
2006; Pollock et al., 2003; Qi et al., 2011; J. Wu et al., 2007; Yazdi et al., 2003), and others 
that report NRAS mutations as more common (Bauer et al., 2007; Carr and Mackie, 1994; 
Charbel et al., 2014; Dessars et al., 2009; Kinsler et al., 2013; D. Wu et al., 2011). These 
inconsistencies may be related to differences in study methodology. For example, some 
studies only sequenced CMN for either BRAF or NRAS mutations, but not both; others 
examined one size of CMN, or failed to describe the size of studied lesions altogether. Many 
of these studies do not report how diagnoses were made, or if lesions diagnosed as CMN 
were documented as being present at birth (Table 1).
More recent studies, which have included different CMN sizes, have refined the picture of 
this genetic landscape, revealing a consistent relationship between the size of lesion and 
mutation status (Table 1). BRAF or NRAS mutations are typically found in small CMN, but 
the prevalence of NRAS mutations is greater among medium to giant CMN. The increase in 
frequency of NRAS mutations is concomitant with a decrease in frequency of BRAF 
mutations. The most recent genetic study, conducted by Charbel et al. using multiple 
powerful sequencing techniques and comparable cohorts of small/medium and large/giant 
CMN documented at birth, affirms this trend. Of the 19 large/giant CMN examined, 18 
(94.7%) were positive for an NRAS mutation and the remaining one harbored a BRAF 
mutation; 6 out of 20 (30%) small/medium CMN carried a BRAF mutation, and the 
remaining 70% were NRAS-mutants (Charbel et al., 2014) (Table 1). The inverse 
relationship between prevalence of BRAF mutations and size of CMN lesion is supported 
further by reports of zero BRAF mutations found in two series of giant CMN (De Raeve et 
al., 2006; D. Wu et al., 2011) and one series of medium/large CMN (Bauer et al., 2007) 
(Table 1).
It was aforementioned that many of these studies do not include statements regarding 
documentation confirming the presence of CMN lesions at birth, or arising shortly 
thereafter. This is an often overlooked weakness of these studies because, as Bauer et al. 
remarks, the diagnosis of CMN is not always made based on a documented history at birth. 
The distinctive histopathologic features of CMN are sometimes used to diagnose nevi with 
an unknown history as “congenital pattern nevi,” and nevi with this classification may be 
grouped together with documented congenital nevi. The accuracy of such diagnoses has 
been evaluated, and it has been repeatedly determined that the classic histopathologic 
features of CMN have limited specificity in predicting which nevi were truly present at birth 
(Bauer et al., 2007; Clemmensen and Kroon, 1988; Cribier et al., 1999; Rhodes et al., 1985). 
Misdiagnosing acquired nevi as congenital would presumably falsely increase the 
prevalence of BRAF mutations since acquired melanocytic nevi have high rates of BRAF 
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mutations (Pollock et al., 2003; Poynter et al., 2006; Uribe et al., 2003). Furthermore, as 
CMN larger than a few centimeters are unlikely to be missed at birth, misdiagnoses based on 
histological features are more likely to occur with small lesions and may account, in part, for 
the high rates of BRAF mutations reported in small CMN. Another potential cause for the 
variation in rates of observed mutations may be due to sampling errors secondary to low 
proportions of mutated nevus cells relative to keratinocytes and stroma, or a clonal 
heterogeneity of nevus cells (Charbel et al., 2014; Ichii-Nakato et al., 2006).
Attempts at molecularly characterizing CMN have primarily focused on genetic aberrations 
in the BRAF and NRAS loci, in part because of the increased risk of melanoma inherent to 
larger CMN (Krengel et al., 2006; Watt et al., 2004) and the prominent role of BRAF and 
NRAS mutations in melanoma biology. It is becoming clearer that different classes of CMN 
likely have different genetic signatures, but our knowledge of these genetic signatures has 
only scratched the surface, with few studies interested in potential targets of mutation other 
than BRAF and NRAS. Papp et al. screened 18 small/medium CMN for mutations and 
deletions in TP53, CDKN2A, and CDK4 genes, and only found two silent mutations in TP53 
(Papp et al., 1999). Kinsler et al. also performed mutational analyses for several genes, 
reporting one incident each of GNAQ and HRAS mutations and 3 KRAS mutations from a 
panel of over two-dozen CMN (Kinsler et al., 2013). Interested in identifying other somatic 
mutations that might be cooperating with NRAS mutations to foster CMN pathogenesis, 
Charbel et al. performed whole exome sequencing on 5 large/giant CMN. After eliminating 
several possible hits as false positives using confirmatory sequencing, the only recurrent 
somatic mutation identified was, unsurprisingly, in the NRAS gene (Charbel et al., 
2014).Shakhova et al. described a mouse model for giant congenital nevi and show that nevi 
and melanoma prominently express Sox10. Sox10 haploinsufficiency counteracts 
NRASQ61K-driven congenital nevus and melanoma formation without affecting the 
physiological functions of neural crest derivatives in the skin. Furthermore, they showed that 
SOX10 silencing in human melanoma cells suppresses neural crest stem cell properties, 
counteracting proliferation and cell survival, and completely abolishes in vivo tumor 
formation (Shakhova et al., 2012). Although much remains to be learned about CMN 
genetics, as sequencing technology continues to advance in accuracy, ease, and cost, it is 
plausible that CMN will one day be classified by genotype rather than phenotype.
ACQUIRED MELANOCYTIC NEVI
The term nevus is derived from a Latin root meaning “birthmark,” implying that nevi are 
present at birth. However, despite the root meaning, the majority of nevi are acquired after 
birth. Interestingly, these acquired nevi share genetic and environmental risk factors with 
malignant melanoma. Individuals with fair skin, a tendency to sunburn, and poor tanning 
ability are at an increased risk for malignant melanoma (Bataille, 2003) and have increased 
number of melanocytic nevi (Bauer and Garbe, 2003). Additionally, several studies 
implicate a propensity to develop melanocytic nevi as an independent risk factor for 
cutaneous melanoma (Bauer and Garbe, 2003). As 20–30% of melanomas arise from 
preexisting melanocytic nevi (Rivers, 2004), it is not surprising that many of the genetic 
underpinnings of melanoma have also been found in nevi.
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The role of the BRAF mutation in the current genetic basis of melanoma development and 
progression is based on the Clark model for melanoma progression (Bennett, 2003), 
corresponding to the proposed morphologic changes from benign nevus to dysplastic nevus 
to melanoma (W. E. Damsky et al., 2014). BRAF mutations were first described in 2003 
(Pollock et al., 2003), with 81.5% (53 of 65) of acquired nevi studied harboring a BRAF 
mutation. Since this report, many benign acquired melanocytic nevi have been analyzed, and 
78% (373/478) were found to have a BRAF mutation; an NRAS mutation was found in only 
6.0% (8/134) of acquired melanocytic nevi (Table 2).
Like melanoma, melanocytic nevi frequently harbor activating BRAF mutations, which are 
thought to be an initial step in melanocytic neoplasia; this idea is supported by the finding 
that inducible expression of BRAFV600E in melanocytes of mice yields melanocytic nevi and 
melanoma (Dhomen et al., 2009). However, the initial growth of a melanocytic nevus is 
followed by loss of proliferative activity and stabilization of size. Mirroring this clinical 
observation, sustained BRAFV600E expression in normal human melanocytes induces cell 
cycle arrest accompanied by the induction of both p16INK4a and acidic β-galactosidase 
activity, which are also demonstrated in lesions of melanoma in situ (Gray-Schopfer et al., 
2006; Michaloglou et al., 2008). Thus, some melanocytic nevi are likely benign clonal 
tumors that temporarily undergo proliferation via oncogenic BRAF signaling followed by 
growth arrest due to oncogene-induced senescence (OIS), a concept discussed later 
(Michaloglou et al., 2008). It is clear that BRAF gene mutations are not sufficient to confer 
malignant change to melanocytes and other factors must play a role. Furthermore, the high 
concordance rate (80.4%) of BRAF mutation between melanoma and its nevus counterpart 
(Tschandl et al., 2013), as well as the occurrence of BRAF wild-type melanoma arising in 
BRAF-mutant nevi (Tan et al., 2015) suggest that other molecular signatures are involved in 
melanoma development.
Distinct dermoscopic structures have been identified that correspond to histopathological 
features of nevi (Yadav et al., 1993). For example, a pigment network (or reticulation) 
corresponds to a junctional, predominantly lentiginous melanocytic proliferation whereas 
globules correspond to large dermal or epidermal melanocytic nests (Argenziano et al., 
2007). Recently, Marchetti et al. showed that the frequency of BRAFV600E mutations differs 
in nevi distinguished by unique dermoscopic structures and microanatomical growth 
patterns (Marchetti et al., 2014). Globular nevi correspond histopathologically to a 
predominantly dermal growth pattern or the presence of large junctional nests, and were 
significantly more likely to express BRAFV600E than reticular nevi(Marchetti et al., 
2014).These finding were overall consistent with previous studies showing that intradermal 
nevi are significantly more likely to have BRAF mutations than juctional nevi(Hafner et al., 
2009; Karram et al., 2013), and that BRAFV600E positive nevi are less likely to have a 
junctional component or show lentiginous growth characteristics compared with BRAF wild-
type nevi (Tschandl et al., 2013).
DYSPLASTIC NEVI
Patients with multiple dysplastic nevi are known to be at higher risk of developing 
cutaneous melanoma. An individual with a single clinically dysplastic nevus has a 2-fold 
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increased risk for melanoma, whereas having greater than 10 clinically dysplastic nevi is 
associated with a 12-fold increased risk (Bataille et al., 1996; Marghoob et al., 1994). 
Moreover, dysplastic nevi are more common in patients with melanoma; 30% of melanomas 
seem to arise in association with nevi, most commonly a dysplastic nevus, and a personal 
and family history of melanoma can significantly increase the incidence of finding 
dysplastic nevi in a patient (Bataille et al., 1996; Seykora and Elder, 1996; Sober and 
Burstein, 1995). When dysplastic nevi were separately analyzed, 57.9 % (84/145) of the nevi 
were positive for a BRAF mutation (Table 3). In the late 1970s, Clark et al. (Clark et al., 
1978) proposed that dysplastic nevi are an evolutionary precursor to melanoma in patients 
with a family history of melanoma (Clark et al., 1984; Rhodes et al., 1983; Rhodes et al., 
1982). However, the biologic and clinical implications of this observation remain unclear as 
benign, normal-appearing acquired melanocytic nevi can also be found in association with 
melanomas (Hastrup et al., 1991; Rhodes et al., 1982).
BLUE NEVI
Blue nevi are a group of acquired, pigmented, dermal dendritic melanocytic proliferations 
comprised of many described variants, the two major ones being common blue nevi and 
cellular blue nevi (Held et al., 2013; Zembowicz and Mihm, 2004; Zembowicz and Phadke, 
2011). Common blue nevi may arise at any age, or be congenital in nature, but have a 
tendency to appear in adolescence, and most often present as a small (<1 cm) solitary, dark 
blue-to-black papule (Argenziano et al., 2007; Gonzalez-Campora et al., 1994; Murali et al., 
2009; Zembowicz and Phadke, 2011). Like common blue nevi, cellular blue nevi occur at all 
ages, but are most common in adults younger than 40 years of age (Murali et al., 2009). 
Cellular blue nevi also have a deep bluish-black color, but present as larger plaques or 
nodules greater than 1 cm, and sometimes several centimeters, in diameter (Zembowicz and 
Phadke, 2011). The distinct color of these lesions is due to the dermal location of the 
melanin, which causes preferential reflection of short-wavelength blue light due to a 
scattering effect known as Tyndall scattering (Zembowicz and Mihm, 2004). Blue nevi have 
a predilection for certain body sites, including the scalp, dorsal surfaces of distal extremities, 
and sacral region; common blue nevi are most often located on extremities, and cellular blue 
nevi most often in the sacral region (Gonzalez-Campora et al., 1994; Temple-Camp et al., 
1988; Zembowicz and Phadke, 2011). It is theorized that blue nevi consistently occur in 
these body regions because these are the sites with active dermal melanocytes at birth, 
whereas melanocytes migrate through and eventually disappear from the majority of the 
body’s dermis during fetal life (Leopold and Richards, 1968; Zembowicz and Phadke, 2011; 
Zimmermann and Cornbleet, 1948). Histologically, blue nevi are dermal lesions that rarely 
have a junctional component (may be present in the case of combined nevi), with the 
diagnostic cell type of common and cellular blue nevi being spindled dendritic and ovoid 
melanocytes, respectively (Held et al., 2013; Zembowicz and Phadke, 2011).
Clinically and histopathologically, blue nevi are distinguishable as an independent class of 
melanocytic proliferations, and genetic studies of blue nevi have provided further support 
that they are a distinct entity separate from acquired melanocytic nevi. Most acquired 
melanocytic nevi harbor somatic mutations in genes involved in the MAPK signaling 
pathway, particularly BRAF and NRAS (Davies et al., 2002; Pollock et al., 2003; Van 
Roh et al. Page 6
Pigment Cell Melanoma Res. Author manuscript; available in PMC 2016 November 01.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
Raamsdonk et al., 2009). Mutations in these genes are uncommonly identified in blue nevi; 
Saldanha et al. reported BRAF exon 15 mutations in 3 (12%) of 25 blue nevi and did not 
identify any NRAS mutations, while Emley et al. reported zero BRAF and 1 (5.3%) NRAS 
mutations in 19 common and cellular blue nevi, but found KRAS mutations among 16.7% 
(3/18) of these blue nevi (Emley et al., 2011; Saldanha et al., 2004).
The observation that mice with activating mutations in the G protein α-subunits, GNAQ and 
GNA11, acquire a phenotype of dermal hyperpigmentation similar in appearance to blue 
nevi in humans prompted the discovery that the majority of blue nevi harbor a somatic 
mutation of either GNAQ or GNA11 (Van Raamsdonk et al., 2004). In their first study, Van 
Raamsdonk et al. sequenced the entire coding regions of these genes in 29 blue nevi and 
reported GNAQ mutations in 24 (82.8%); no GNA11 mutations were reported (Van 
Raamsdonk et al., 2009). In a follow up study, out of a group of 96 common and cellular 
blue nevi, 65 (67.7%) and 8 (8.3%) harbored GNAQ and GNA11 mutations respectively, 
with all but one affecting glutamine at codon 209 (Q209) (Van Raamsdonk et al., 2010). 
More recently, a genetic analysis of 30 common and cellular blue nevi revealed that 86.7% 
(26/30) and 3.6% (1/28) had GNAQ and GNA11 mutations, respectively, all in codon 209 
(Bender et al., 2013). The previously mentioned study by Emley et al. reported a lower 
prevalence of GNAQ mutations in common and cellular blue nevi, as only 42.1% (8/19) 
lesions carried mutations, but once again, all were in codon 209 (Emley et al., 2011). These 
mutations cause a loss of GTPase activity, leading to constitutive activation and subsequent 
upregulation of MAPK pathway signaling, a consequence also seen with constitutively 
active mutated BRAF and NRAS. Additionally, like mutated BRAF and NRAS, in vivo 
tumorigenicity studies have shown that, although mutated GNAQ acts as an oncogenic 
protein, it is not sufficient for melanomagenesis when acting alone (Van Raamsdonk et al., 
2009). This is corroborated by the generally benign and stable nature of blue nevi, which 
rarely progress to malignancy.
Genetic analyses of rare blue nevi variants and blue nevi-related dermal melanocytoses (i.e. 
Nevus of Ito and Nevus of Ota) are sparse, with small sample sizes, but the findings tend to 
agree that GNAQ and GNA11 mutations are much less prevalent in these lesions than in 
common and cellular blue nevi (Bender et al., 2013; Emley et al., 2011; Held et al., 2013; 
Van Raamsdonk et al., 2009; Van Raamsdonk et al., 2010). Further genetic studies and 
functional validation investigations are needed to better elucidate how GNAQ and GNA11 
mutations influence the biology and pathophysiology of blue nevi and related dermal 
melanocytic lesions.
SPITZ NEVI
Spitz tumors are a subgroup of melanocytic neoplasms, ranging from benign to malignant, 
with a predominance of large epithelioid or spindled melanocytes. Cases on the benign end 
of the spectrum, with no overlapping morphologic features of melanoma are designated as 
Spitz nevi, whereas cases with unequivocal features of melanoma are designated as spitzoid 
melanoma. Consistent with Spitz nevi’s lack of morphologic features of melanoma, the 
genetics of Spitz nevi also do not align well with melanoma. BRAF and NRAS mutations are 
prevalent in melanomas, but the majority of studies investigating the genetic status of Spitz 
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nevi (Table 4) have demonstrated an absence of these mutations. In total, BRAF and NRAS 
mutations were detected in 6.4% (21/330) and 2.2% (4/178) of Spitz nevi respectively 
(Table 4). The most frequently observed genetic alterations in Spitz nevi involve the HRAS 
gene; an aggregate of data from multiple studies revealed 48 of 293 (16.4%) Spitz nevi 
harbored HRAS alterations (copy number gain or mutation) (Table 4). HRAS belongs to the 
family of RAS genes, which contains two additional members, KRAS and NRAS (Barbacid, 
1987). In contrast to NRAS, HRAS is rarely mutated in melanoma (Jiveskog et al., 1998; van 
Elsas et al., 1996). HRAS mutation seems to occur almost exclusively in Spitz nevi. Bastian 
et al. first described HRAS copy number amplification in 23.5% (4/17) of Spitz nevi in 1999, 
and subsequently confirmed the presence of increased HRAS copy number in 11.8% 
(12/102) of Spitz nevi, while also showing HRAS mutations in 66.7% (8/12) of the Spitz 
nevi with increased copy number (Bastian et al., 2000; Bastian et al., 1999). HRAS is known 
to have higher affinity for the PI3K/ATK pathway when compared to other RAS isoforms 
(Yan et al., 1998), however, the significance of HRAS mutations in the nevogenesis of Spitz 
nevi remains unclear. It has been suggested that HRAS drives the symmetrical overgrowth 
of cells with epitheloid morphology via preferential PI3K/AKT activation, without marked 
increase of the melanin activation pathway (Ross et al., 2011). Clinically, the presence of an 
HRAS mutation seems to be associated with a favorable prognosis. Thus far, studies have 
found no metastases in patients with HRAS-mutated Spitz tumors, and no HRAS mutations 
have been reported in Spitzoid melanomas with distant metastasis or fatal outcome (Da 
Forno et al., 2009; Takata et al., 2007; van Dijk et al., 2005; van Engen-van Grunsven et al., 
2010). Based on the frequency of HRAS mutations in Spitz nevi and the lack thereof in 
spitzoid melanomas, it seems unlikely that HRAS-mutated Spitz nevi progress to spitzoid 
melanomas.
Another subset of spitzoid neoplasms are characterized by BRAF mutations combined with 
bi-allelic BAP1 loss (Wiesner et al., 2012; Wiesner et al., 2011). BAP1 is a deubiquitinating 
enzyme whose gene is located on chromosome region 3p12 (Jensen et al., 1998). BAP1 has 
been suggested to be a tumor suppressor gene with a role in cell proliferation and growth 
inhibition (Jensen and Rauscher, 1999). This subset of melanocytic neoplasm described by 
Wiesner et al. histologically resembled so-called “atypical Spitz tumors” (ASTs), which are 
an ill-defined and heterogeneous group of melanocytic tumors that display histologic 
features seen in both Spitz nevi and melanoma. These BRAF mutant tumors had similar 
cytologic features to Spitzoid tumors characterized by HRAS mutations, however, the HRAS 
mutant neoplasms were associated with marked desmoplasia and did not show dense cellular 
aggregates compared to BRAFV600E/BAP1−/− tumors (Wiesner et al., 2012).
Recently, gene rearrangements of ROS1, NTRK1, ALK, BRAF, and RET, resulting in in-
frame kinase fusions, were reported through genomic analysis of 140 Spitzoid neoplasms 
(Wiesner et al., 2014). These kinase fusions occurred across the entire biologic spectrum of 
spitzoid neoplasms, including Spitz nevi, ASTs, and spitzoid melanoma. All fusions 
occurred in a mutually exclusive pattern, and no fusions were detected in tumors with HRAS 
mutations (Wiesner et al., 2014). The results of the study suggest that these fusions occur 
early in the pathogenesis of spitzoid neoplasms and are therefore necessary, but not 
sufficient, for malignant transformation. In this respect, the oncogenic role of these gene 
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arrangements seems to be similar to that of mutations in oncogenes (such as BRAF, NRAS, 
GNAQ, and GNA11) commonly found in melanocytic neoplasms (Wiesner et al., 2014).
NEVI AND MELANOMAGENESIS
To understand the molecular basis of melanomagenesis, it is imperative to identify the 
genetic changes that facilitate the different steps in progression from normal melanocyte to 
nevus and melanoma. Commonly, an initial “driver” mutation, either activation of an 
oncogene or the loss of a tumor suppressor gene, triggers the establishment of a benign 
growth. After this initial phase of proliferation, a senescence program is executed, causing 
termination of the tumor expansion. Cellular senescence is a physiologic process by which 
cells gradually lose their growth potential and eventually exit cell cycle progression. In 
normal human cells, senescence can occur due to either telomere shortening that takes place 
after a certain number of cell divisions (replicative senescence) (Dimri et al., 1996) or, 
paradoxically, because of the aberrant activation of oncogenes (oncogene-induced 
senescence) (Serrano et al., 1997). In humans, naturally occurring oncogene-induced 
senescence (OIS) is best exemplified by acquired melanocytic nevi and CMN, which 
represent benign aggregations of non-proliferative melanocytes that often harbor activating 
mutations in BRAF and NRAS genes, respectively. Michaloglou et al. showed that 
overexpression of BRAFV600 in cultured human melanocytes caused growth arrest and also 
observed hallmarks of OIS in human congenital melanocytic nevi: expression of an 
activated oncoprotein (BRAFV600), stable and total, or near-total, proliferative arrest, 
upregulation of a tumor suppressor (p16INK4A), and emergence of senescence-associated 
acidic β-galactosidase (Michaloglou et al., 2008). Additionally, there was no significant 
difference in telomere fluorescence between congenital nevi and surrounding tissues, which 
supports results from common acquired nevi and Spitz nevi (Miracco et al., 2002), and 
further suggests that nevi are growth arrested due to OIS rather than replicative senescence. 
In spite of the activation of the MAPK pathway (RAS/RAF/MEK/ERK) that mediates a 
potent proliferative signal, benign nevi eventually lose all proliferative activity, and their 
growth remains arrested for decades, until they gradually disappear; however, with 
additional genetic alterations, a few nevus cells can develop into malignant melanoma 
(Kuwata et al., 1993; Maldonado et al., 2004). In large CMN, Charbel et al. demonstrated 
that after birth, certain large CMN cell subtypes still display clonogenic potential and can 
expand into nevus-like structures when interacting with adjacent keratinocytes(Charbel et 
al., 2015). This explains nevus secondary resurgences, which have been described following 
nevus excisions, as well as the natural expansion of nevi during childhood.
It is widely believed that a substantial percentage of melanomas arise from melanocytic nevi 
(Mooi and Peeper, 2006) and several groups have provided genetic evidence that supports 
the progression model (Bogdan et al., 2003; Dadzie et al., 2009; Demunter et al., 2001). It 
seems that OIS, similar to apoptosis, is a fail-safe mechanism to prevent malignant 
transformation of normal cells. Therefore, overcoming OIS may act as a rate-limiting event 
for melanomagenesis (Bennett, 2003; Mooi and Peeper, 2006). That is, only upon the 
emergence of additional tumorigenic alterations can a malignant process occur. The 
molecular mechanisms underlying this malignant transformation from nevus to melanoma 
are not yet resolved. Loss of p16INK4A has long been suspected to play a critical role in the 
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abrogation of OIS and collective evidence support a redundant role for p16INK4A in 
senescence induced by mutant BRAF or NRAS in vitro (Michaloglou et al., 2008) and in vivo 
(Dhomen et al., 2009). Another common genetic event in melanoma is activation of the 
PI3K pathway (Dhawan et al., 2002). Vredeveld et al. recently demonstrated that PI3K 
pathway activation serves as a critical event in melanomas arising from nevi, acting in part 
by abrogating OIS (Vredeveld et al., 2012). They showed that PTEN depletion and 
consequent activation of the PI3K pathway abrogates BRAFV600E-induced senescence. 
Similarly, Damsky et al. reported that simultaneous Cdnk2a and Lkb1 inactivation in 
BRAFV600E melanocytes results in activation of both mTORC1 and Akt/mTORC2, inducing 
rapid melanoma formation in mice (W. Damsky et al., 2015). Loss of Cdkn2a is insufficient 
to release melanocytes from OIS; however, this primes a subset of growth-arrested, 
BRAFV600E nevi for later stochastic progression to melanoma, which appears to occur 
through activation of Akt/mTORC2 and mTORC1 signaling (W. Damsky et al., 2015).
Melanomas associated with nevi have been studied thoroughly with the hope of better 
understanding melanoma biology. Tschandl et al. demonstrated that no significant 
difference in the distribution of BRAF or NRAS mutations is found between melanomas and 
associated nevi or between melanoma-associated nevi and control nevi (Tschandl et al., 
2013). Notably, this study concludes that the presence of a BRAFV600E or NRASQ61 
mutation within a nevus does not alter the risk of malignant transformation. A recent meta-
analysis of 13 studies, with 4,346 cumulative patients, revealed that 32% of melanomas are 
associated with a nevus, however, there was no prognostic implication in sentinel lymph 
node status or overall survival for these nevus-associated melanomas compared to de novo 
melanomas (Lin et al., 2015).
Since the use of specific BRAFV600E inhibitors has become more commonplace in the 
treatment of melanoma, interesting findings have been reported regarding the effect of these 
drugs on benign nevi, which frequently harbor BRAFV600E mutations (Pollock et al., 2003); 
(Dalle et al., 2011; Haenssle et al., 2012). Dermoscopic changes to preexisting nevi in color, 
appearance and disappearance of globules, dermoscopic island pigmentation, and increases 
in size have been reported following BRAF inhibitor therapy (Perier-Muzet et al., 2014). 
Interestingly, the evolving nevi were BRAFV600E mutated while the stable nevi were BRAF 
wild-type. This phenomenon maybe related to decreased MAPK pathway activity due to 
BRAF inhibition (McClenahan et al., 2014). Others have reported that BRAFV600E 
inhibitor-treated patients show increased size and pigmentation in some nevi and 
development of new BRAF wild-type melanomas driven by paradoxical MAPK activation 
(Hatzivassiliou et al., 2010). Clearly, BRAF and its associated pathway are linked to 
nevogenesis and stability, but larger studies are required to better understand escape 
pathways and paradoxical MAPK pathway activation.
SUMMARY
Nevi are a heterogeneous group of benign melanocytic neoplasms, with varying clinical and 
molecular characteristics. While the molecular etiology of nevi have been less thoroughly 
studied than melanoma, it is clear that nevi and melanoma share common driver mutations. 
Acquired melanocytic nevi harbor oncogenic mutations in BRAF, which is the predominant 
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oncogene associated with melanoma. While congenital melanocytic nevi, blue nevi, and 
acquired nevi predominantly harbor NRAS mutations, GNAQ mutations, and BRAF 
alterations, respectively, Spitz nevi and spitzoid tumors have now been linked to an 
assortment of oncogenic drivers including HRAS and BAP1 alterations and kinase fusions 
(Figure 1). Excepting HRAS, all of the “nevus” genes have also been described in melanoma 
development and progression. Thus, the distinction between melanoma and nevi seems to be 
a nevus cell’s ability to undergo senescence after sustaining pro-proliferative mutations. 
Melanoma’s ability to escape this senescence pathway, tipping the balance from benign 
neoplasm to malignancy, remains an area of active investigation. The genetics of nevi have 
not been as thoroughly studied as its malignant counterpart, despite the potential to provide 
insight into how melanomas undergo malignant transformation. Molecular studies have been 
limited by a lack of robust nevi mouse models and limited availability of excised tissue for 
analysis. Nevertheless, further genetic studies of nevi promise to shape our understanding of 
melanoma and the delicate tipping-point from benign neoplasm to malignancy.
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Figure 1. The RAS Signaling pathways and Nevi
MAPK signaling promotes cell growth and survival and is constitutively active in nevi. RAS 
family members are activated by receptor tyrosine kinases and signal through effector 
proteins, including RAF kinases and PI3K. Acquired melanocytic nevi harbor oncogenic 
mutations in BRAF, which is the predominant oncogene associated with melanoma. 
Congenital melanocytic nevi, blue nevi, and Spitz nevi frequently harbor NRAS mutations, 
GNAQ mutations, and HRAS alterations, respectively (Modified from N Engl J Med. 2010 
Sep 30;363(14):1352-60 Copyright © (2010) Massachusetts Medical Society. Reprinted 
with permission.)
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Figure 2. 
Clinical images of nevi. Subtypes of nevi include large CMN (A), medium CMN (B), 
melanoma arising in CMN (C), intradermal nevus (D), acral junctional nevus (E), dysplastic 
nevus (F), blue nevus (G), and Spitz nevus (H).
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Table 2
Studies evaluating the mutation status of BRAF and NRAS in acquired melanocytic nevi
Study Histology of nevi
analyzed*
BRAF
mutations
NRAS
mutations
(Jafari et al., 1995) Benign nevi -- 0/5 (0%)
(Pollock et al., 2003)
Intradermal 37/42(88%) --
Compound 16/23(70%) --
(Dong et al., 2003) Benign melanocytic nevi 17/24(70.8%) 0/24(0%)
(Saldanha et al., 2004) Common acquired nevi 14/16(87.5%) 2/11(18.2%)
(Poynter et al., 2006) Benign melanocytic nevi 42/51(82.3%) 3/51(5.9%)
(Ichii-Nakato et al., 2006) Common acquired nevi 105/120(87.5%) --
(Uribe et al., 2006) Common acquired nevi 16/24(66.7%) --
(Bloethner et al., 2007) Benign melanocytic nevi 18/30(60%) --
(J. Wu et al., 2007) Common acquired nevi 83/101(82.2%) --
(Venesio et al., 2008)
Compound nevi 6/13(46.2%) 0/13(0%)
Intradermal nevi 3/6(50%) 0/6(0%)
Junctional nevi 2/3(66.7%) 0/3(0%)
(Tschandl et al., 2013) Control nevi 14/25(56%) 3/21(14.3%)
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Table 3
Studies evaluating the mutation status of BRAF in dysplastic nevi
Study Nevi included BRAF
mutations
NRAS
mutations
(Pollock et al., 2003) Dysplastic nevi 4/5(80%) --
(Papp et al., 2005) Dysplastic nevi 4/18(22%) --
(Uribe et al., 2006) Atypical nevi 13/21(61.9%) --
(Saroufim et al., 2014) Dysplastic nevi 63/125(55.8%) --
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Table 4
Studies evaluating the genetic alteration status of BRAF, NRAS, and HRAS in Spitz nevi.
Study Histological
Subtypes
BRAF
mutations
NRAS
mutations
HRAS
alterations
(Bastian et al., 1999) Spitz Nevi -- -- 4/17(23.5%)*
(Bastian et al., 2000) Spitz Nevi -- -- 12/102(12%)*
(Yazdi et al., 2003) Spitz Nevi 0/69(0%) -- --
(Palmedo et al., 2004) Spitz Nevi 0/21(0%) -- --
(Mihic-Probst et al., 2004) Spitz Nevi 0/20(0%) -- --
(Saldanha et al., 2004) Spitz Nevi 0/26(0%) 1/16(6.25%) --
(Gill et al., 2004) Spitz Nevi 0/30(0%) 0/30(0%) 0/30(0%)
(Turner et al., 2005) Spitz Nevi 0/24(0%) -- --
(van Dijk et al., 2005) Spitz Nevi and Atypical Spitz Nevi 0/30(0%) 0/30(0%) 6/30(20%)
(Fullen et al., 2006) Spitz Nevi 10/48(20.8%) 1/48(2.08%) --
(La Porta et al., 2006) Spitz Nevi 8/8(100%) -- --
(Takata et al., 2007) Spitz Nevi 0/12(0%) 0/12(0%) 0/12(0%)
(Da Forno et al., 2009) Spitz Nevi and Atypical Spitz Nevi 2/22(9.1%) 2/22(9.1%) 2/19(10.5%)
(Emley et al., 2010) Spitz Nevi and Atypical Spitz Nevi 1/20(5%) 0/20(0%) --
(van Engen-van Grunsven et al., 2010) Spitz Nevi -- -- 24/93(25.8%)
*
These studies reported frequency of copy number gain, not mutation
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